Products
The fixed combination of beclomethasone dipropionate and formoterol was approved in many countries in 2019 in the form of a metered-dose inhaler with a compressed-gas inhalation solution. In other countries, the drug has been registered for longer, for example in Germany since 2006. The powder inhalers have not yet been approved in many countries.
Structure and properties
The active ingredients are contained in the drug as beclomethasone dipropionate and formoterol fumarate dihydrate. This is also referred to as an ICS / LABA fixed combination.
Effects
Beclomethasone dipropionate is a glucocorticoid with anti-inflammatory, immunosuppressive, and antiallergic properties. Formoterol is a selective beta2-sympathomimetic with bronchodilator properties. Its effects occur rapidly, within 1 to 3 minutes, and last for about 12 hours.
Indications
- Bronchial asthma
- Chronic obstructive pulmonary disease (COPD)
Dosage
According to the professional information. The drug can be used for both maintenance and as-needed therapy. For maintenance therapy, inhalation is usually used in the morning and evening. To avoid the development of oral thrush, the mouth should be rinsed with water after inhalation. Additionally, gargle to clear the throat. Alternatively, the teeth can also be brushed. Adequate patient education is required for inhaler use.
Contraindications
- Hypersensitivity
Full details of precautions and interactions can be found in the drug label.
Adverse effects
The most common possible adverse effects include pharyngitis (pharyngitis), oral thrush, dysphonia (voice disorder), pneumonia (pneumonia, in COPD), and [headache.
